Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Characterization of Phenotypes in Gstm1-null Mice by Cytosolic and in Vivo Metabolic Studies Using 1,2-Dichloro-4-Nitrobenzene

Kazunori Fujimoto, Shingo Arakawa, Yukari Shibaya, Hiroaki Miida, Yosuke Ando, Hiroaki Yasumo, Ayako Hara, Minoru Uchiyama, Haruo Iwabuchi, Wataru Takasaki, Sunao Manabe and Takashi Yamoto
Drug Metabolism and Disposition September 2006, 34 (9) 1495-1501; DOI: https://doi.org/10.1124/dmd.106.010009
Kazunori Fujimoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shingo Arakawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yukari Shibaya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroaki Miida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yosuke Ando
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroaki Yasumo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ayako Hara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minoru Uchiyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haruo Iwabuchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wataru Takasaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sunao Manabe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Yamoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Glutathione S-transferase Mu 1 (GSTM1) has been regarded as one of the key enzymes involved in phase II reactions in the liver, because of its high expression level. In this study, we generated mice with disrupted glutathione S-transferase Mu 1 gene (Gstm1-null mice) by gene targeting, and characterized the phenotypes by cytosolic and in vivo studies. The resulting Gstm1-null mice appeared to be normal and were fertile. Expression analyses for the Gstm1-null mice revealed a deletion of Gstm1 mRNA and a small decrease in glutathione S-transferase alpha 3 mRNA. In the enzymatic study, GST activities toward 1,2-dichloro-4-nitrobenzene (DCNB) and 1-chloro-2,4-dinitrobenzene (CDNB) in the liver and kidney cytosols were markedly lower in Gstm1-null mice than in the wild-type control. Gstm1-null mice had GST activities of only 6.1 to 21.0% of the wild-type control to DCNB and 26.0 to 78.6% of the wild-type control to CDNB. After a single oral administration of DCNB to Gstm1-null mice, the plasma concentration of DCNB showed larger AUC0–24 (5.1–5.3 times, versus the wild-type control) and higher Cmax (2.1–2.2 times, versus the wild-type control), with a correspondingly lower level of glutathione-related metabolite (AUC0–24, 9.4–17.9%; and Cmax, 9.7–15.6% of the wild-type control). In conclusion, Gstm1-null mice showed markedly low ability for glutathione conjugation to DCNB in the cytosol and in vivo and would be useful as a deficient model of GSTM1 for absorption, distribution, metabolism, and excretion/toxicology studies.

Glutathione S-transferases (GSTs) form a superfamily that is characterized by catalysis of the conjugation of glutathione (GSH) with various electrophilic compounds (Hayes and Pulford, 1995). At least seven distinct classes (Alpha, Mu, Pi, Sigma, Theta, Kappa, and Zeta) of soluble GSTs have been identified so far, according to substrate specificity, chemical affinity, structure, and the kinetic behavior of the enzyme (Landi, 2000; Strange et al., 2000). However, a large number of GST isoforms that overlap the substrates' specificities and broad GST expression in various tissues do not encourage the characterization of the properties for each GST isoform in the whole body.

The use of knockout mice with one disrupted gene among a large number of xenobiotic-metabolizing enzyme isoforms shows great advantages in understanding the pharma/toxicokinetics of xenobiotics. Three knockout mice lines for GST isoforms, Gsta4 KO mice (Engle et al., 2004), Gstp1/p2 KO mice (Henderson et al., 1998, 2000; Elsby et al., 2003), and Gstz1 KO mice (Fernandez-Canon et al., 2002; Lim et al., 2004), have been established so far. However, the pharma/toxicokinetics of the specific substrate for the GST isoform in these knockout mice lines has not been analyzed yet, and there are only a few reports about the pharma/toxicokinetics of the specific substrate in the knockout mice with disrupted xenobiotic-metabolizing enzyme genes other than GSTs.

In mouse, GSTA3, GSTP1, and GSTM1 show high expression levels in the liver and kidney, and have been regarded as the key enzymes for phase II reaction and the detoxification of carcinogens/mutagens, environmental pollutants, and anticancer drugs (Mitchell et al., 1997). In this study, we focused on GSTM1, which is one of six Mu class GST isoforms in mice (Hayes and Pulford, 1995; Guo et al., 2002), and generated mice with disrupted glutathione S-transferase Mu 1 gene (Gstm1-null mice) by gene targeting. We characterized the phenotypes by in vitro and in vivo metabolic studies.

Materials and Methods

Generation ofGstm1-null Mice. To construct the targeting vector, DNA from W9.5 ES cells was used to amplify Gstm1 genomic fragments for both the 5′ and 3′ arms. For the 5′ arm, a 6.8-kb 5′-flanking sequence of the Gstm1 gene was cloned into the HpaI and XhoI sites of the pKO Scrambler V901 plasmid. For the 3′ arm, a 3.0-kb 3′-flanking sequence of the Gstm1 gene was cloned into the SacII and SalI sites. The primers for the 5′ arm were 5′-AGTGTTAACATGCTTTATTCATTCTTCCGACATC-3′ and 5′-CCCCTCGAGAGTTACAGGAACAGTCGGTGACATG-3′. The primers for the 3′ arm were 5′-AGACCGCGGGGTCTCTCCACCTTGCACATGCCAC-3′ and 5′-CGCGTCGACACAGCATTCTCGTGAAAGATGTTTG-3′. For the positive-negative selection, a neomycin-resistant (Neor) cassette from the pKO SelectNeo V800 plasmid and diphtheria toxin A chain gene (DT) from pKO SelectDT V840 plasmid was used. All plasmids were supplied from TAKARA BIO Inc. (Ohtsu, Japan). W9.5 ES cells (107) were electroporated (250 V, 500 μF) with 20 μg of the linearized targeting vector and selected with 250 μg (active form)/ml G418 for 8 to 10 days (Fujimoto et al., 2006). G418-resistant clones were primarily screened on the 3′ arm by PCR with the primer pair, NeoF3: 5′-CTGCTAAAGCGCATGCTCCAGACTGCCTTG-3′ and M1R2: 5′-ACCTGTGAACTGGAGATCCAGAGCTCTTAC-3′. The PCR-positive clones were twice checked on the 5′ arm by PCR with the primer pair, GM2H: 5′-AGTGTTAACTTGTGAGGTTGACACAGAACTCTG-3′ and NP3: 5′-AATGAGGAAATTGCATCGCATT-3′. Finally, the homologous recombination was confirmed by the direct sequence of the amplified PCR fragments on both regions using an ABI PRISM 3700 DNA Analyzer (Applied Biosystems, Foster city, CA). Chimera mice were generated using the targeted ES cell clone by an aggregation method (Wood et al., 1993). Male chimera mice were mated with C57BL/6J females, and homozygous mutant (Gstm1-null) mice were obtained by intercrossing the heterozygotes. Their genotype was determined by PCR using two forward primers (NeoRF for the mutant allele: 5′-ACTTGTGTAGCGCCAAGTGCCCA-3′, and GSTM1-WF for the wild allele: 5′-TCTCCTTGAGGAATGATGAGGCT-3′) and one common reverse primer (GSTM1-WR: 5′-TTCTCCATGCCAGGAGAACTCTA-3′). Mice were housed under a controlled temperature (23 ± 1°C) with free access to water and mouse chow. The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Sankyo Co., Ltd.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Targeted disruption of the mouse Gstm1 gene. A, the targeting vector construct (top), the wild allele of the Gstm1 gene (middle), and the predicted mutant allele (bottom). The targeting vector was constructed by replacing the entire Gstm1 gene containing 8 exons (E1–E8) with a neomycin-resistant (Neor) cassette. The Diphtheria toxin A chain gene (DT) fragment was ligated at the 5′ end of the vector for negative selection. The mutant allele was detectable by PCR using the indicated primer sets, GM2H/NP3 and NeoF3/M1R2, which confirmed the homologous recombination on the 5′ and 3′ arm, respectively. B, PCR analyses of the homologous recombination on the 5′ and 3′ arm. GM2H/NP3 primer set was amplified by a 7.15-kb fragment contained in the 5′ arm on the mutant allele (left). NeoF3/M1R2 primer set was amplified by a 3.1-kb fragment contained in the 3′ arm on the mutant allele (right). Lambda/HindIII digest was used as a molecular size marker. wt, wild type.

Gstm1,Gsta3, andGstp1mRNA Expression Analysis. To analyze the GST isoform gene expression, total RNA was isolated from the livers of the Gstm1-null mice, the heterozygotes, and the wild-type controls. After DNase I treatment, cDNAs were synthesized using an oligo(dT) primer and SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA). RT-PCR was performed using the primers specific for the mouse Gstm1 gene (forward: 5′-GCTCATCATGCTCTGTTACAAC-3′, and reverse: 5′-TGTAGCAAGGGCCTACTTGT-3′) and β-actin gene (forward: 5′-ATGGAATCCTGTGGCATCCATG-3′, and reverse: 5′-TAGAAGCACTTGCGGTGCACGAT-3′). Real-time quantitative RT-PCR for the mouse Gsta3, Gstp1, and Gapdh genes was performed using the TaqMan Gene Expression Assays (Applied Biosystems) and qPCR Mastermix Plus (Nippon EGT, Toyama, Japan). The mRNA content level was quantified with a GeneAmp 5700 Sequence Detection System (Applied Biosystems), according to the manufacturer's instruction.

Measurement of the GST Activities Toward CDNB and DCNB in the Cytosols of the Liver and Kidney. The liver and kidney samples of the Gstm1-null mice, the heterozygotes, and the wild-type controls were mixed with 1.15% potassium chloride (1:3, w/v) and homogenized in an ice bath. The homogenates were centrifuged at 9000g for 20 min at 4°C, and the supernatant fraction was further centrifuged at 105,000g for 1 h at 4°C to isolate the cytosolic fraction. Protein concentrations in the cytosolic fractions were determined by the method of Lowry et al. (1951). The GST activity toward CDNB (GST-C activity) was measured according to the established method (Habig et al., 1974). Briefly, the cytosol was diluted 30-fold with 1.15% potassium chloride, and 0.3 ml of 20 mM GSH and 0.06 ml of the diluted cytosol were mixed in 5.34 ml of 100 mM potassium phosphate buffer (pH 6.5). After the addition of CDNB at a final concentration of 1 mM, the change in absorbance at 340 nm was measured for 1 min with a spectrophotometer. The GST activity toward DCNB (GST-D activity) was measured according to the established method (Habig et al., 1974). Briefly, the cytosol was diluted 30-fold with 1.15% potassium chloride, and 0.3 ml of 100 mM GSH and 0.1 ml of the cytosol were mixed with 5.3 ml of 100 mM potassium phosphate buffer (pH 7.5). After addition of DCNB at a final concentration of 1 mM, the change in absorbance at 345 nm was measured for 1 min with a spectrophotometer. The GST-C and GST-D activities were expressed as the amount of CDNB-GSH and DCNB-GSH conjugate moles formed per unit weight of protein per unit of time, respectively.

Measurement of Plasma DCNB and the Metabolites Concentrations After Administration of DCNB.Gstm1-null mice and the wild-type controls were treated via oral administration with 1% DCNB dissolved in polyethylene glycol at dose levels of 100 mg/kg. Approximately 0.3 ml of blood was collected at 30 min, and 1, 2, 4, 8, and 24 h postdose. The blood samples were centrifuged at 10,000 rpm for 5 min at 4°C to prepare the plasma samples. Then, 50 μl of each plasma sample was mixed with 150 μl of ethanol and centrifuged at 3000 rpm for 5 min at 4°C. To determine the plasma concentration of DCNB, the supernatant was subjected to a high-performance liquid chromatography (HPLC) system (Shimadzu Corporation, Kyoto, Japan) consisting of a system controller (SCL-10A), a pump (LC-10AD), an autosampler (SIL-10AXL), a column oven (CTO-10AC), and a UV detector (SPD-10A). The HPLC conditions for this analysis were as follows: the column was an L-column ODS (150 × 4.6 mm i.d.; Chemicals Evaluation and Research Institute, Tokyo, Japan); the column temperature was 40°C; mobile phase was water/acetonitrile/ammonium acetate (1 M) at 65:35:1 (v/v/v); flow rate was 1.0 ml/min; injection volume was 20 μl; and UV detector wavelength was 270 nm.

LC-MS and LC-MS/MS Analyses. LC-MS and LC-MS/MS analyses were performed using a Q-Tof mass spectrometer (Waters, Manchester, UK) with an HPLC system (Hitachi High-Technologies Corp., Tokyo, Japan) consisting of an intelligent pump (model L-7100), a column oven (model L-7300), a chromato-integrator (model D-7500), and a UV detector (model L-7400S). The LC-MS analysis was conducted using electrospray ionization (ESI) in the positive ion mode. The capillary voltage and cone voltage were set at 3300 V and 45 V, respectively. The source temperature and desolvation gas temperature were 120°C and 300°C, respectively. The mass range from m/z 50 to 900 was acquired with an integration time of 1 s. The LC-MS/MS experiments were performed using a collision energy of 20 eV and xenon as the collision gas. The chromatographic separation was carried out on a YMC-Pack ODS-A A-312 column (6.0 × 150 mm; YMC Corporation, Kyoto, Japan), the column temperature was maintained at 40°C, and UV detection was at 270 nm. The mobile phase used was water/acetonitrile/ammonium acetate (1 M) at a ratio of 82:18:1 (v/v/v). The flow rate was set at 0.1 ml/min and the elution flow from HPLC was introduced into the Q-Tof ionization source through an ESI interface.

Statistical Analysis. The values of the mean and the standard deviation in each group were calculated with statistical software (SAS System Version 5.0; SAS Institute Inc., Cary, NC). A parametric Dunnett's test for the mean value was performed to analyze the differences between the wild-type control and the hetero/homozygote. A value of P < 0.05 was chosen as an indication of statistical significance.

Results

Generation ofGstm1-null Mice. Mice with disrupted Gstm1 gene were generated by a homologous recombination method with a mouse ES cell. The targeting vector used in this study is shown in Fig. 1A. Mouse Gstm1 gene consists of eight exons in a region of approximately 5.7 kb. This targeting vector was designed to achieve the deletion of the entire coding region of the Gstm1 gene by replacing it with a Neor cassette. W9.5 ES cells were electroporated with the targeting vector, and 288 of the colonies with G418 resistance were selected and screened by PCR for homologous recombination. Two independent PCR-positive clones, 4B3 and 10C4, were obtained by primary PCR screening with a NeoF3/M1R2 primer pair (Fig. 1B, right). However, secondary PCR screening with a GM2H/NP3 primer pair revealed that only the 4B3 clone was integrated into the targeted sequence by homologous recombination (Fig. 1B left). The 4B3 ES cells were aggregated with two zona pellucida-free eight-cell embryos from C57BL/6J mice and cultured for 24 h. Aggregated blastocysts were transferred into the uterus of the surrogate mothers. Chimera mice were identified by coat color and crossed to C57BL/6J mice, and F1 heterozygous offspring to which the targeted ES cells had contributed were identified by coat color and PCR genotyping. Furthermore, the F1 heterozygous mice were intercrossed to produce F2 mice, which were determined to be wild-type (+/+), heterozygotes (+/–), or homozygotes (–/–; Gstm1-null mice) by PCR genotyping (Fig. 2A). Gstm1-null mice appeared to be normal and were fertile as the wild-type and heterozygote. No obvious histological, hematological, and blood chemical differences in the basal condition were detected between Gstm1-null mice and the wild-type control (data not shown).

Gstm1,Gsta3, andGstp1mRNA Expression Analysis.Gstm1 mRNA expression was not detected in the livers of Gstm1-null mice by RT-PCR (Fig. 2B). This result indicates a disruption of the Gstm1 gene in Gstm1-null mice. Furthermore, to confirm whether Gstm1 gene disruption has an effect on Gsta3 and Gstp1 mRNA expression, the expression levels in the livers of Gstm1-null mice were determined by real-time quantitative RT-PCR. These results revealed slightly low Gsta3 mRNA expression levels (male, 64.7%; female, 86.5% of the wild-type control), despite the same levels of Gstp1 mRNA expression in the livers of Gstm1-null mice (Fig. 3).

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

PCR genotyping and RT-PCR analysis of Gstm1-null mice. +/+, +/–, and –/– indicate wild-type, heterozygote, and homozygote, respectively. A, the genotype was determined by PCR using two forward primers distinctive between the wild allele and the mutant allele, and one common reverse primer. The wild allele and the mutant allele indicated a 154-bp fragment and a 236-bp fragment, respectively. Phi X174/HincII digest was used as a molecular size marker. B, RT-PCR was performed using the primers specific for the mouse Gstm1 gene and β-actin gene. The amplified fragments were confirmed by direct sequence using the ABI PRISM 3700 DNA Analyzer.

GST-C and GST-D Activity in the Cytosol of the Liver and Kidney. We measured the GST-C and GST-D activity in cytosolic samples from the livers and kidneys of Gstm1-null mice. The results revealed low GST-C and GST-D activity in the Gstm1-null mice (Fig. 4). GST-C activity was slightly low in the liver of the males (78.6% of the wild-type control), and markedly low in the liver of females (32.3% of the wild-type control) and in the kidneys of both sexes (male, 26.0%; female, 33.8% of the wild-type control). GST-D activity was nearly absent in the livers and the kidneys of both sexes (male liver, 9.9%; female liver, 8.7%; male kidney, 6.1%; female kidney, 21.0% of the wild-type control). The heterozygotes showed intermediate GST-C and GST-D activity between that of the homozygotes and wild-types in the all-cytosolic samples.

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Quantification of Gsta3 and Gstp1 mRNA in the liver of Gstm1-null mice. Messenger RNA from the livers of each five mice was qualified by the TaqMan Gene Expression Assays (Applied Biosystems) using Gapdh mRNA as an internal control. The open and filled bars indicate wild-type and Gstm1-null mice, respectively. The values are depicted as the mean ± S.D. of five mice per group. *, P < 0.01; significant difference from the wild-type.

Fig. 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 4.

GST-C and GST-D activity in a cytosolic sample of the liver and kidney. Enzymatic activity was measured spectrophotometrically. Open, gray, and filled bars indicate wild-type, heterozygote, and homozygote, respectively. The values are depicted as the mean ± S.D. of five mice per group. *, P < 0.05; **, P < 0.005; ***, P < 0.001; significant difference from the wild-type.

Plasma Concentrations of DCNB and Its Metabolite, M0, After Administration of DCNB. We measured the plasma concentrations of DCNB after a single oral administration of DCNB (100 mg/kg) to wild-type and Gstm1-null mice by HPLC, to evaluate the pharmacokinetics of DCNB in the whole body. This result is shown in Fig. 5. The AUC0–24 was 6.04 ± 0.62 μg · h/ml in the male wild-type control, 31.72 ± 9.44 μg · h/ml in the male Gstm1-null mice, 9.02 ± 1.27 μg · h/ml in the female wild-type control, and 45.99 ± 5.34 μg · h/ml in the female Gstm1-null mice. The Cmax was 1.76 ± 0.53 μg/ml in the male wild-type control, 3.73 ± 0.62 μg/ml in the male Gstm1-null mice, 1.95 ± 0.23 μg/ml in the female wild-type control, and 4.30 ± 0.22 μg/ml in the female Gstm1-null mice. After a single oral administration of DCNB to Gstm1-null mice, the plasma concentration of DCNB showed a larger AUC0–24 (male, 5.3 times; female, 5.1 times, versus the wild-type control) and higher Cmax (male, 2.1 times; female, 2.2 times, versus the wild-type control). Furthermore, three peaks were determined in the plasma after administration of DCNB to the wild-type control, as major metabolite peaks in the HPLC chromatogram. As shown in Fig. 6, the concentration of M0, which had the highest level among the three metabolites, was lower in the plasma of Gstm1-null mice. After a single oral administration of DCNB, Gstm1-null mice showed smaller AUC0–24 (male, 9.4%; female, 17.9% of the wild-type control) and lower Cmax (male, 9.7%; female, 15.6% of the wild-type control).

Structure Analysis of Metabolite M0. The DCNB metabolite, M0, was detectable in mouse plasma. The molecular-related ion [M + H]+ of M0 was observed at m/z 248 in the positive ion mode. Thus, the molecular weight of metabolite M0 was proposed to be 247. The LC-MS/MS spectrum of the precursor ion [M + H]+ at m/z 248 and major fragment ions are shown in Fig. 7. The fragment ion at m/z 206 was formed via elimination of the acetyl moiety from the ion at m/z 248. The fragment ion at m/z 170 was formed via elimination of the methylsulfone moiety from the ion at m/z 248. In addition, the most intense fragment ion at m/z 127 was formed by loss of the acetyl moiety and the methylsulfone moiety from the ion at m/z 248. As well, a high resolution LC-ESI/MS analysis demonstrated the elemental composition of the molecular-related ion [M + H]+ at m/z 248 to be C9H11NO3SCl (data not shown), which supports the fact that metabolite M0 is a methylsulfone-N-acetyl form of DCNB. Therefore, the chemical structure of M0 was found to be a methylsulfone-N-acetyl form produced by the glutathione conjugation of the DCNB followed by several metabolic reactions.

Fig. 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 5.

Plasma DCNB concentrations after a single-dose oral administration of DCNB (100 mg/kg) to Gstm1-null mice or the wild-type control. Open and filled squares indicate wild-type control and Gstm1-null mice, respectively. The values are depicted as the mean ± S.E.M. of three mice per group.

Discussion

We generated mice with disrupted Gstm1 gene, which is expressed predominantly in the liver, by homologous recombination, to investigate the properties of mouse GSTM1 in xenobiotic metabolism. An ES cell clone with the predicted mutant allele, confirmed by genomic PCR and sequencing analyses, was used to generate mice with disrupted Gstm1 gene. RT-PCR analysis revealed a lack of Gstm1 mRNA expression in the homozygote. Furthermore, two-dimensional difference gel electrophoresis/mass spectrometry analyses also revealed that GSTM1 protein expression was completely absent in the homozygotes (data not shown). These results indicated success in the generation of the Gstm1-null mice.

In the enzymatic study, GST-D activity was nearly absent in the livers and kidneys of both sexes in Gstm1-null mice. Mouse GSTM1 purified from liver cytosol has been reported to specifically catalyze DCNB (Warholm et al., 1986). The present study also clarified that DCNB is a specific substrate for mouse GSTM1. Conversely, Gstm1-null mice showed low GST-C activity (approximately 30% of the wild-type control) in the kidneys of both sexes and in the female livers, and a slightly low GST-C activity (approximately 80% of the wild-type control) in the male livers. Interestingly, GST-C activities with broad specificity to various GSTs were lower than our expectation in the male and female kidneys and the female livers of the Gstm1-null mice, indicating that GSTM1 is the main enzyme to catalyze CDNB metabolism in mouse male and female kidneys and female livers. The higher hepatic GST-C activity in the male Gstm1-null mice may be due to the higher expression of pi class GSTs in males than females (Mitchell et al., 1997).

Fig. 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 6.

Plasma M0 concentrations after a single-dose oral administration of DCNB (100 mg/kg) to Gstm1-null mice or the wild-type control. Open and filled squares indicate wild-type control and Gstm1-null mice, respectively. The values are depicted as mean ± S.E.M. of three mice per group.

Plasma DCNB concentrations after an administration of DCNB to Gstm1-null mice showed larger AUC0–24 (male, 5.3 times; female, 5.1 times, versus the wild-type control) and higher Cmax (male, 2.1 times; female, 2.2 times, versus the wild-type control), consistent with lower GST-D activity in vitro. In the same way, the concentration of M0, the major metabolite among the three DCNB metabolites separated on the HPLC chromatogram, showed a smaller AUC0–24 in the plasma (male, 9.4%; female, 17.9% of the wild-type control) and lower Cmax (male, 9.7%; female, 15.6% of the wild-type control) in Gstm1-null mice. This suggested that M0 might be a GSH-related metabolite of DCNB. Actually, the structure analysis by LC-MS/MS revealed that M0 was the GSH-related metabolite, the methylsulfone-N-acetyl form (Bray et al., 1957a,b; Zhang et al., 2003). Considering these results, Gstm1-null mice administered the specific substrate for mouse GSTM1, such as DCNB, are highly exposed and toxicologically susceptible to the substrate. Therefore, we conclude that Gstm1-null mice would be useful as a toxicokinetically modified animal model, i.e., an animal model of a poor metabolizer to the specific substrates for mouse GSTM1.

We performed comprehensive gene expression analysis of the livers of the Gstm1-null mice and the wild-type controls using Affymetrix GeneChip microarray. This result showed that no GST isoforms were up-regulated in Gstm1-null mice (data not shown), different from the case of Gsta4-null mice and Gstz1-null mice (Engle et al., 2004; Lim et al., 2004). In Gstm1-null mice, a slightly low expression level of Gsta3 mRNA was observed by the GeneChip microarray and real-time quantitative RT-PCR analyses, despite there being no change in the Gstp1 mRNA expression level. It has actually been reported that mouse GSTA3 has low GST-C and GST-D activities (Hayes and Pulford, 1995). From these results and available information, the slight down-regulation of the Gsta3 mRNA expression might be involved in the low GST-C and GST-D activities in Gstm1-null mice established in this study.

Fig. 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 7.

MS/MS spectrum of metabolite M0 and proposed assignments of the fragment ions.

GSTs are important enzymes for xenobiotic metabolism and toxic phenotype. However, a large number of GST isoforms overlap the substrates' specificities, and a broad GST expression in various tissues could not facilitate the characterization of the properties of each GST isoform in the whole body. The GST knockout mice would facilitate the investigation of these properties and help to understand the metabolic pathways through the GST isoforms (Hayes et al., 2005). However, only a few reports on GST knockout mice have been published so far. In the present study, we generated knockout mice for the Gstm1 gene and clarified that the GSTM1 deficiency results in markedly low GST-D activity both in vitro and in vivo. Furthermore, it has been reported that mouse GSTM1 inhibits apoptosis signal-regulating kinase 1 (ASK1) by forming GSTM1/ASK1 complex and mediates apoptosis in response to heat shock stress (Cho et al., 2001; Dorion et al., 2002). These observations suggest that GSTM1 is responsible not only as a xenobiotic-metabolizing enzyme but also as a cellular signaling factor. Gstm1-null mice would be useful to analyze the apoptosis signaling via GSTM1 in vivo.

In conclusion, we generated knockout mice for the Gstm1 gene and found that GST-D activity in the liver and kidney cytosols markedly decreased in Gstm1-null mice, and that a single oral administration of DCNB to Gstm1-null mice resulted in larger AUC and higher Cmax for the plasma concentration of DCNB, and smaller AUC and lower Cmax for the plasma concentration of M0, a GSH-related metabolite of DCNB. This mouse model would be useful as an animal model exhibiting poor metabolism of the specific substrates to mouse GSTM1 for absorption, distribution, metabolism, and excretion/toxicology study.

Acknowledgments

We thank T. Matsuura, Y. Aida, S. Yamauchi, K. Watanabe, and M. Kiyosawa for their excellent technical assistance.

Footnotes

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.106.010009.

  • ABBREVIATIONS: GST, glutathione S-transferase; GSTM1, glutathione S-transferase Mu 1; GSTa or GSTa, glutathione S-transferase Alpha; Gstp, glutathione S-transferase Pi; Gstz, glutathione S-transferase Zeta; GSH, glutathione; KO, knockout; ES cell, embryonic stem cell; kb, kilobase(s); DT, diphtheria toxin A chain gene; RT-PCR, reverse transcription-polymerase chain reaction; DCNB, 1,2-dichloro-4-nitrobenzene; CDNB, 1-chloro-2,4-dinitrobenzene; GST-D activity, GST activity toward DCNB; GST-C activity, GST activity toward CDNB; HPLC, high-performance liquid chromatography; LC-MS, liquid chromatography-tandem mass spectrometry; LC-MS/MS, liquid chromatography-tandem mass spectrometry; ESI, electrospray ionization; ASK1, apoptosis signal-regulating kinase 1; bp, base pair(s).

    • Received March 5, 2006.
    • Accepted June 5, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    Bray HG, James SP, and Thorpe WV (1957a) The metabolism of 2:4-, 2:5- and 3:4-dichloronitrobenzene in the rabbit. Biochem J 65: 483–490.
    OpenUrlFREE Full Text
  2. ↵
    Bray HG, James SP, and Thorpe WV (1957b) The metabolism of 2:3-, 2:6- and 3:5-dichloronitrobenzene in the rabbit. Biochem J 67: 607–616.
    OpenUrlFREE Full Text
  3. ↵
    Cho SG, Lee YH, Park HS, Ryoo K, Kang KW, Park J, Eom SJ, Kim MJ, Chang TS, Choi SY, et al. (2001) Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1. J Biol Chem 276: 12749–12755.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Dorion S, Lambert H, and Landry J (2002) Activation of the p38 signaling pathway by heat shock involves the dissociation of glutathione S-transferase mu from Ask1. J Biol Chem 277: 30792–30797.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Elsby R, Kitteringham NR, Goldring CE, Lovatt CA, Chamberlain M, Henderson CJ, Wolf CR, and Park BK (2003) Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase Pi. J Biol Chem 278: 22243–22249.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Engle MR, Singh SP, Czernik PJ, Gaddy D, Montague DC, Ceci JD, Yang Y, Awasthi S, Awasthi YC, and Zimniak P (2004) Physiological role of mGSTA4-4, a glutathione S-transferase metabolizing 4-hydroxynonenal: generation and analysis of mGsta4 null mouse. Toxicol Appl Pharmacol 194: 296–308.
    OpenUrlCrossRefPubMed
  7. ↵
    Fernandez-Canon JM, Baetscher MW, Finegold M, Burlingame T, Gibson KM, and Grompe M (2002) Maleylacetoacetate isomerase (MAAI/GSTZ)-deficient mice reveal a glutathione-dependent nonenzymatic bypass in tyrosine catabolism. Mol Cell Biol 22: 4943–4951.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Fujimoto K, Koishi R, Shimizugawa T, and Ando Y (2006) Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity. Exp Anim 55: 27–34.
    OpenUrlCrossRefPubMed
  9. ↵
    Guo J, Zimniak L, Zimniak P, Orchard JL, and Singh SV (2002) Cloning and expression of a novel Mu class murine glutathione transferase isoenzyme. Biochem J 366: 817–824.
    OpenUrlPubMed
  10. ↵
    Habig WH, Pabst MJ, and Jakoby WB (1974) Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249: 7130–7139.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Hayes JD, Flanagan JU, and Jowsey IR (2005) Glutathione transferases. Annu Rev Pharmacol Toxicol 45: 51–88.
    OpenUrlCrossRefPubMed
  12. ↵
    Hayes JD and Pulford DJ (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30: 445–600.
    OpenUrlCrossRefPubMed
  13. ↵
    Henderson CJ, Smith AG, Ure J, Brown K, Bacon EJ, and Wolf CR (1998) Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc Natl Acad Sci USA 95: 5275–5280.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Henderson CJ, Wolf CR, Kitteringham N, Powell H, Otto D, and Park BK (2000) Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci USA 97: 12741–12745.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Landi S (2000) Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat Res 463: 247–283.
    OpenUrlCrossRefPubMed
  16. ↵
    Lim CE, Matthaei K, Blackbum AC, Davis RP, Dahlstrom JE, Koina ME, Anders MW, and Board PG (2004) Mice deficient in glutathione transferase zeta/maleylacetoacetate isomerase exhibit a range of pathological changes and elevated expression of alpha, mu, and pi class glutathione transferases. Am J Pathol 165: 679–693.
    OpenUrlCrossRefPubMed
  17. ↵
    Lowry OH, Rosebrough HJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275.
    OpenUrlFREE Full Text
  18. ↵
    Mitchell AE, Morin D, Lakritz J, and Jones AD (1997) Quantitative profiling of tissue- and gender-related expression of glutathione S-transferase isoenzymes in the mouse. Biochem J 325: 207–216.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Strange RC, Jones PW, and Fryer AA (2000) Glutathione S-transferase: genetics and role in toxicology. Toxicol Lett 112–113: 357–363.
    OpenUrlCrossRefPubMed
  20. ↵
    Warholm M, Jensson H, Tahir MK, and Mannervik B (1986) Purification and characterization of three distinct glutathione transferase from mouse liver. Biochemistry 25: 4119–4125.
    OpenUrlCrossRefPubMed
  21. ↵
    Wood SA, Allen ND, Rossant J, Auerbach A, and Nagy A (1993) Non-injection methods for the production of embryonic stem cell-embryo chimaeras. Nature (Lond) 365: 87–89.
    OpenUrlCrossRefPubMed
  22. ↵
    Zhang JY, Yuan JJ, Wang YF, Bible RH Jr, and Breau AP (2003) Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice. Drug Metab Dispos 31: 491–501.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 34 (9)
Drug Metabolism and Disposition
Vol. 34, Issue 9
1 Sep 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of Phenotypes in Gstm1-null Mice by Cytosolic and in Vivo Metabolic Studies Using 1,2-Dichloro-4-Nitrobenzene
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Characterization of Phenotypes in Gstm1-null Mice by Cytosolic and in Vivo Metabolic Studies Using 1,2-Dichloro-4-Nitrobenzene

Kazunori Fujimoto, Shingo Arakawa, Yukari Shibaya, Hiroaki Miida, Yosuke Ando, Hiroaki Yasumo, Ayako Hara, Minoru Uchiyama, Haruo Iwabuchi, Wataru Takasaki, Sunao Manabe and Takashi Yamoto
Drug Metabolism and Disposition September 1, 2006, 34 (9) 1495-1501; DOI: https://doi.org/10.1124/dmd.106.010009

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Characterization of Phenotypes in Gstm1-null Mice by Cytosolic and in Vivo Metabolic Studies Using 1,2-Dichloro-4-Nitrobenzene

Kazunori Fujimoto, Shingo Arakawa, Yukari Shibaya, Hiroaki Miida, Yosuke Ando, Hiroaki Yasumo, Ayako Hara, Minoru Uchiyama, Haruo Iwabuchi, Wataru Takasaki, Sunao Manabe and Takashi Yamoto
Drug Metabolism and Disposition September 1, 2006, 34 (9) 1495-1501; DOI: https://doi.org/10.1124/dmd.106.010009
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • New Dog P450 3A98 in Gut
  • TMDD Affects PK of IL-10 Fc-Fusion Proteins
  • In Vitro Models to Study P-gp-Mediated Intestinal DDIs
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics